



SAFETY DATA SHEET

Revision date 13-Jun-2025

Version 4

Page 1 / 14

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Product Code(s) PZ03094
Trade Name: Labetalol Hydrochloride Injection, USP
Chemical Family: Not determined

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as cardiovascular drug

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

Reproductive toxicity Category 2 - (H361f)

OSHA Classification

Hazards not otherwise classified (HNOC)

Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

2.2. Label elements

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 2 / 14
Version 4



Signal word

Warning

Hazard statements

H361f - Suspected of damaging fertility

Precautionary Statements - EU (§28, 1272/2008)

P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood

P280 - Wear protective gloves/protective clothing/eye protection/face protection

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P405 - Store locked up

P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Chemical name	EU - REACH (1907/2006) - Article 59(1) - Candidate List of Substances of Very High Concern (SVHC) for Authorisation	EU - REACH (1907/2006) - Endocrine Disruptor Assessment List of Substances
Propylparaben	-	Endocrine disrupting properties

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Labetalol Hydrochloride	0.5		251-211-1	Repr 2 (H361f)	Not classified	No data available	No data available

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 3 / 14
Version 4

(CAS #: 32780-64-6)							
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5 (011-002-00-6)	Skin Corr. 1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
Citric acid monohydrate (CAS #: 5949-29-1)	**	-	Not Listed	Skin Irrit. 2 (H315) Eye Irrit. 2 (H319) STOT SE 3 (H335)	Not classified	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available
Propylparaben (CAS #: 94-13-3)	*		202-307-7	Not classified	Not classified	No data available	No data available
Methyl-p-hydroxybenzoate (CAS #: 99-76-3)	*		202-785-7	Not classified	Not classified	No data available	No data available
Edetate disodium (CAS #: 139-33-3)	*		205-358-3	Not classified	Not classified	No data available	No data available
Dextrose (CAS #: 14431-43-7)	*		Not Listed	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Edetate disodium 139-33-3	2000	No data available	No data available	No data available	No data available
Labetalol Hydrochloride 32780-64-6	2114	No data available	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration >=0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59).

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 4 / 14
Version 4

Additional information

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
-------------------------------------	--

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians	None.
--------------------	-------

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media	Dry chemical, CO2, alcohol-resistant foam or water spray.
------------------------------	---

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical	Not applicable.
Hazardous combustion products	Formation of toxic gases is possible during heating or fire. May include oxides of carbon.
Explosion data	
Sensitivity to mechanical impact	No information available.
Sensitivity to static discharge	No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.
--	--

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 5 / 14
Version 4

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.
Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Labetalol Hydrochloride

Pfizer OEL TWA-8 Hr: 200 µg/m³

Propylparaben

Russia

MAC: 10 mg/m³

Methyl-p-hydroxybenzoate

Russia

MAC: 4 mg/m³

Edetate disodium

Russia

MAC: 2 mg/m³

Sodium hydroxide

ACGIH OEL (Ceiling)

2 mg/m³

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 6 / 14
Version 4

ACGIH TLV	Ceiling: 2 mg/m ³
Austria	TWA-TMW: 2 mg/m ³ ; inhalable fraction
	STEL-KZGW: 4 mg/m ³ (8 X 5 min); inhalable fraction
Bulgaria	TWA: 2.0 mg/m ³ ; alkaline aerosols
Czech Republic	1 mg/m ³
	Ceiling: 2 mg/m ³
Denmark	Ceiling: 2 mg/m ³ ;
Estonia	TWA: 1 mg/m ³ ;
	STEL: 2 mg/m ³ ;
Finland	Ceiling: 2 mg/m ³ ;
France	2 mg/m ³
Hungary	TWA-AK: 1 mg/m ³ ;
	STEL-CK: 2 mg/m ³ ;
Ireland	STEL: 2 mg/m ³ ;
Ceiling Limit Value	2 mg/m ³
Latvia	TWA: 0.5 mg/m ³ ;
Poland	TWA-NDS: 0.5 mg/m ³ ;
	STEL-NDSch: 1 mg/m ³ ;
Romania	TWA: 1 mg/m ³ ;
	STEL: 3 mg/m ³ ;
Slovakia	TWA: 2 mg/m ³ ;
Spain	STEL (VLA-EC): 2 mg/m ³ ;
Switzerland	TWA-MAK: 2 mg/m ³ ; inhalable dust
	STEL-KZGW: 2 mg/m ³ ; inhalable dust
OSHA PEL	TWA: 2 mg/m ³
	(vacated) Ceiling: 2 mg/m ³
United Kingdom	STEL: 2 mg/m ³ ;

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal protective equipment

Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 7 / 14
Version 4

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

Thermal hazards No information available.

Environmental exposure controls No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Liquid
Color	Colorless to light yellow
Odor	No information available.
Odor threshold	No information available
Property	Values
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	3.0-4.5
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available Soluble
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	Mixture
Molecular weight	Mixture

9.2.1. Information with regard to physical hazard classes

No information available

Oxidizing properties	None
-----------------------------	------

9.2.2. Other safety characteristics

No information available

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 8 / 14
Version 4

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual ingredients

Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include nausea, vomiting, shortness of breath (dyspnea); tiredness, low blood pressure on standing (orthostatic hypotension), abnormal ejaculation, impotence

Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	Based on available data, the classification criteria are not met.
STOT - single exposure	Based on available data, the classification criteria are not met.
STOT - repeated exposure	Based on available data, the classification criteria are not met.
Reproductive toxicity	Classification is based on mixture calculation methods based on component data.
Germ cell mutagenicity	Based on available data, the classification criteria are not met.
Carcinogenicity	Based on available data, the classification criteria are not met.
Aspiration hazard	Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Propylparaben

Mouse Oral LD 50 6332 mg/kg

Mouse Sub-tenon injection (eye) LD 50 200 mg/kg

Methyl-p-hydroxybenzoate

Mouse Oral LD50 > 8 g/kg

Rat Oral LD 50 2100 mg/kg

Edetate disodium

Rat Oral LD50 2000-2200 mg/kg

Labetalol Hydrochloride

Rat Oral LD50 2114 mg/kg

Mouse Oral LD50 600 mg/kg

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 9 / 14
Version 4

Rabbit Oral LD50 1250 mg/kg
Rat Intravenous LD50 53 mg/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Edetate disodium	= 2 g/kg (Rat)	-	-
Labetalol Hydrochloride	= 2114 mg/kg (Rat)	-	-
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-

Irritation / Sensitization: (Study Type, Species, Severity)

Methyl-p-hydroxybenzoate

Skin irritation Rabbit Non-irritating
Eye irritation Rabbit Slight
Skin Sensitization Guinea Pig Negative

Citric acid monohydrate

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Moderate

Sodium hydroxide

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Severe

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Propylparaben

3 Week(s) Rat Oral 27.1 g/kg LOAEL Endocrine system
4 Week(s) Rat Oral 347.2 mg/kg LOAEL Male reproductive system

Methyl-p-hydroxybenzoate

28 Day(s) Rat Oral 250 mg/kg/day NOAEL Gastrointestinal System, Spleen, Thymus

Labetalol Hydrochloride

1 Year(s) Rat Oral 1 mg/kg/day LOAEL Heart
1 Year(s) Dog Oral 25 mg/kg/day LOAEL None identified
1 Month(s) Rat Oral 50 mg/kg/day NOAEL None identified

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Methyl-p-hydroxybenzoate

Embryo / Fetal Development Rabbit Oral 300 mg/kg/day NOEL Maternal toxicity, Developmental toxicity

Labetalol Hydrochloride

Reproductive & Fertility Rat Oral 50 mg/kg/day LOAEL Fertility
Embryo / Fetal Development Rat Oral 125 mg/kg/day NOAEL Not Teratogenic, Embryotoxicity
Embryo / Fetal Development Rabbit Oral 4 times human dose NOAEL Not Teratogenic

Reproductive Effects Adverse reproductive effects were observed in human males during therapeutic use.

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Methyl-p-hydroxybenzoate

In Vivo Dominant Lethal Assay Rat Negative

Labetalol Hydrochloride

Bacterial Mutagenicity (Ames) Bacteria Negative
Dominant Lethal Assay Rat Negative
Dominant Lethal Assay Mouse Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Labetalol Hydrochloride

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 10 / 14
Version 4

18 Month(s) Mouse Oral 200 mg/kg/day NOAEL Not carcinogenic

113-116 Week(s) Rat Oral 225 mg/kg/day NOAEL Not carcinogenic

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Methyl-p-hydroxybenzoate

Oryzias latipes (Japanese Rice Fish) OECD LC50 96 hours 59.5 mg/L

Daphnia magna (Water Flea) ISO EC50 48 hours 11.2 mg/L

12.2. Persistence and degradability

Persistence and degradability

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Methyl-p-hydroxybenzoate

OECD Activated sludge Ultimate (CO2 Evolution) 89 % After 28 Day(s) Ready

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
Propylparaben	Not PBT/vPvB
Methyl-p-hydroxybenzoate	Not PBT/vPvB
Edetate disodium	Not PBT/vPvB PBT assessment does not apply
Citric acid monohydrate	Not PBT/vPvB
Sodium hydroxide	Not PBT/vPvB PBT assessment does not apply

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 11 / 14
Version 4

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects No information available.

PMT or vPvM properties Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

Propylparaben

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	202-307-7
AICS	Present

Methyl-p-hydroxybenzoate

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 12 / 14
Version 4

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	202-785-7
AICS	Present
Edetate disodium	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	205-358-3
AICS	Present
Dextrose	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present
Labetalol Hydrochloride	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	251-211-1
Sodium hydroxide	
CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6
Citric acid monohydrate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present

National regulations

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905

Not applicable

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable

Storage of Hazardous Material Not applicable

WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20 Not applicable

Major Accidents Ordinance SR 814.012 Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 13 / 14
Version 4

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide 1310-73-2	75	-

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing Chemicals Inventory
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances
NZIoC - New Zealand Inventory of Chemicals
TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H314 - Causes severe skin burns and eye damage H361f - Suspected of damaging fertility H315 - Causes skin irritation H319 - Causes serious eye irritation H335 - May cause respiratory irritation

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 6 - Accidental Release Measures. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 16 - Other Information.

Revision date 13-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

SAFETY DATA SHEET

Product Name Labetalol Hydrochloride Injection, USP (Hospira Inc.)
Revision date 13-Jun-2025

Page 14 / 14
Version 4

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.